• Home
  • Editorial Board
  • Articles
    • Editorials
    • Guest Articles
  • News
    • Featured
    • Biotech News
  • Interviews
    • Interviews – Academia
    • Interviews – Industry
  • Issues – Archives
  • Subscribe
  • Contact
Facebook Twitter Instagram
Trending
  • Special Issue-Exclusive coverage of BRIC-NIAB
  • India’s Rare Disease updates by Prof. Ramaiah Muthyala
  • Indian Scientists published positive results of first in nation ‘Hemophilia A’ gene therapy
  • Unlocking the Potential: Microalgae as a Sustainable Aquafeed Ingredient
  • Indian scientists developed World’s only farmers’ suit “Kisan Kavach” which can protect them from harmful pesticides
  • 3 Nobel Prizes in 2024 went to biotech and allied scientists
  • USFDA approves Biocon Biologics’ biosimilar for Crohn’s disease, psoriasis
  • Dr. Soumya Swaminathan Honored with FABA Lifetime Achievement Award for Contributions to Global Health
Sunday, June 1
Facebook Twitter Instagram LinkedIn
Biotech Express
  • Home
  • Editorial Board
  • Articles
    • Editorials
    • Guest Articles
  • News
    • Featured
    • Biotech News
  • Interviews
    1. Interviews – Academia
    2. Interviews – Industry
    Featured
    04/01/20241

    Interview: Reach to common man is the heart and soul of India International Science Festival- Dr. Arvind C Ranade Chief Coordinator, IISF- 2023

    Recent
    04/01/2024

    Interview: Reach to common man is the heart and soul of India International Science Festival- Dr. Arvind C Ranade Chief Coordinator, IISF- 2023

    22/05/2023

    Prof Rajeev Varshney becomes the 4th Indian Agricultural Scientist to be elected as Fellow of the Royal Society

    26/07/2022

    We are making best hygiene solutions through Biotech applications: Dr Rachna Dave, founder MicroGO

  • Issues – Archives
  • Subscribe
  • Contact
Biotech Express
You are at:Home»Controversial»Fresh doubts over data integrity in Pfizer mRNA trial

Fresh doubts over data integrity in Pfizer mRNA trial

1
By Biotech Express on 01/12/2021 Controversial, SARS- CoV2 & COVID-19 Updates

Leaked documents have cast fresh doubts over the integrity of data arising from Pfizer’s pivotal COVID-19 vaccine trial and suggest problems at Ventavia are ongoing. 

Earlier this month, whistle-blower Brook Jackson, raised serious concerns about ‘falsified data’ in Pfizer’s mRNA trial (Comirnaty) to The BMJ. The concerns were corroborated by two former Ventavia employees.

Ventavia, the Texas-based company at the centre of the controversy, released a statement claiming that, in respect of Ms Jackson, “no part of her job responsibilities concerned the clinical trials at issue.”

Undeterred, Ms Jackson fired back. Ventavia and its spokesperson Lauren Foreman, were served with a cease-and-desist letter, by attorney Robert Barnes, acting on behalf of whistle-blower, Ms Jackson.

Of Ventavia’s claims, the demand letter says:

“This statement is false. This statement impugns the reputation of my client, Brook Jackson, and falsely implies she publicly misrepresented her work on the clinical trials.”

Attorney Barnes is calling for Ventavia to immediately issue a public retraction and to “formally and publicly apologise” to Ms Jackson.

Her letter of offer for employment indicates Ms Jackson was hired as a “regional director” by Ventavia on 7 Sept 2020. She has almost two decades of experience in clinical trial co-ordination and management behind her.

Leaked documents support Ms Jackson’s observations and raise even more questions.

There were multiple examples of “laboratory processing logs” filled in by staff which contained glaring inconsistencies and anomalies in specimen handling.

Ventavia appeared to be aware of the need to make improvements and Ms Jackson was recruited for the very purpose of improving their quality control.

Among the documents is a list of Ventavia’s outstanding “action items”, which include discussions with trial co-ordinators about the integrity of data.

The list was dated 11 August 2020 and shows that Ventavia had concerns about data falsification even before Ms Jackson’s arrival.

Ms Jackson said the work environment at Ventavia was chaotic, that they were understaffed and that trial participants would be left, unmonitored in the hallway, due to a back log of visits and a lack of space.

The issues were so egregious according to Ms Jackson, that she suggested Ventavia “immediately pause the recruitment of trial participants,” in order to address the issues.

The breaches included improper informed consent forms (ICFs), unblinded staff (vaccine assignment was indicated on the forms), and mismatched signatures (according to Ms Jackson, staff would forge patient signatures if they were missing).

Ms Jackson says that when she raised her concerns with Ventavia, the environment became hostile.

After filing a formal complaint with the FDA on 25 Sept 2020, she was fired the same day.

The FDA did not investigate the site, despite receiving credible allegations of clinical trial misconduct.

The documents show that the problems were not limited to a single issue or employee, but were pervasive and persistent, putting patients at risk and likely to impact data integrity.

Leaked documents now suggest that problems with quality control in the current phase III trials were not corrected following Ms Jackson’s complaint.

 

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Biotech Express
  • Website
  • Facebook
  • Twitter
  • LinkedIn

ISSN: 2454-6968 | Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports, Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology, Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurosciences, Genetics, Medical Sciences, BioPharma etc.

Related Posts

72% of biomedical researchers think field is facing a reproducibility crisis: Survey

Nobel prize-winner tallies two more retractions, bringing total to 13

Cancer paper retracted 11 years after reported plagiarism

1 Comment

  1. Nope on 08/12/2021 11:36 am

    I totally believe this lady. Of course they would falsified records all for the almighty trillions they have made.

    Reply

Leave A Reply Cancel Reply

Current Issue – January 2025
Biotech Express – e-ISSN: 2454-6968

Editorial Board

For Authors – Article Submission and Guidelines

Peer Review Policies

License and Copyright

Advertisement

Recent Posts
  • Special Issue-Exclusive coverage of BRIC-NIAB 15/02/2025
  • India’s Rare Disease updates by Prof. Ramaiah Muthyala 02/01/2025
  • Indian Scientists published positive results of first in nation ‘Hemophilia A’ gene therapy 28/12/2024
  • Unlocking the Potential: Microalgae as a Sustainable Aquafeed Ingredient 27/12/2024
  • Indian scientists developed World’s only farmers’ suit “Kisan Kavach” which can protect them from harmful pesticides 26/12/2024
  • 3 Nobel Prizes in 2024 went to biotech and allied scientists 13/12/2024
  • USFDA approves Biocon Biologics’ biosimilar for Crohn’s disease, psoriasis 01/12/2024
  • Dr. Soumya Swaminathan Honored with FABA Lifetime Achievement Award for Contributions to Global Health 23/11/2024
  • Scientists’ team led by Dr Tapan K Mondal claims Indian tea has independent origin after decoding its first ever Whole Genome 23/11/2024
  • Prof. K C Bansal Elected as a Fellow of The World Academy of Sciences (TWAS) 22/11/2024
Archives
Categories
  • Articles
  • Biotech News
  • Controversial
  • Editorials
  • Events
  • Featured
  • Guest Articles
  • Interviews
  • Interviews – Academia
  • Interviews – Industry
  • News-Industry
  • News-Research
  • Policies
  • SARS- CoV2 & COVID-19 Updates
  • Start-ups
About Us

About Biotech Express

Advisory and Editorial Board

Contact Us

Submission Policy and Guidelines

Submission policies

 

 

Follow us on Social Media
  • Facebook
  • Twitter
  • YouTube
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies. Copyright © 2013-2025 Biotech Express except certain content provided by third parties.

Type above and press Enter to search. Press Esc to cancel.